Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy

Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy · Investor's Business Daily
ALLISON GATLIN
2 min read

In This Article:

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.

Recommended Stories